MedTrace Logo

The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.

NCT04342819 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-09-03

Study results available
· View outcomes & findings →

Summary

The mechanistic effects of empagliflozin on platelet function profiles have not yet been ascertained.

Conditions

  • Platelet Dysfunction Due to Drugs

Interventions

DRUG

SGLT2 inhibitor

Sodium-Glucose Like Transporter 2 Inhibitor

Sponsors & Collaborators

  • The University of The West Indies

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-12-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • Trinidad and Tobago

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04342819 on ClinicalTrials.gov